10538-32-6

Basic information

• Product Name: northioridazine
• Synonyms: northioridazine;2-(Methylthio)-10-[2-(2-piperidinyl)ethyl]-10H-phenothiazine;2-Methylthio-10-[2-(piperidine-2-yl)ethyl]-10H-phenothiazine;N-Desmethythioridazine;Northioridazin;TPD-6
• CAS NO: 10538-32-6
• Molecular Formula: C₂₀H₂₄N₂S₂
• Molecular Weight: 356.54796
• Mol File: 10538-32-6.mol

Chemical Properties

• Boiling Point: 524.6°C at 760 mmHg
• Flash Point: 271°C
• Appearance: /
• Density: 1.25g/cm³
• Vapor Pressure: 4.26E-11mmHg at 25°C
• Refractive Index: 1.683
• PKA: 10.27±0.10(Predicted)
• CAS DataBase Reference: northioridazine(CAS DataBase Reference)
• NIST Chemistry Reference: northioridazine(10538-32-6)
• EPA Substance Registry System: northioridazine(10538-32-6)

Safety Data

• Hazardous Substances Data: 10538-32-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C20H24N2S2/c1-23-16-8-9-20-18(13-16)22(12-10-15-5-4-11-21-14-15)17-6-2-3-7-19(17)24-20/h2-3,6-9,13,15,21H,4-5,10-12,14H2,1H3

Upstream product

• 50-52-2 thioridazine 
• 1484-84-0 2(RS)-(2-hydroxyethyl)piperidine 
• 210564-52-6 t-butyl 2-(2-bromoethyl)piperidine-1-carboxylate 
• 118811-03-3 tert-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate 
• 130-61-0 thioridazine Hydrochloride 

Relevant articles and documents

Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis

The neuroleptic drug thioridazine has been recently repositioned as possible anti-tubercular drug. Thioridazine showed anti-tubercular activity against drug resistant mycobacteria but it is endowed with adverse side effects. A small library of thioridazine derivatives has been designed through the replacement of the piperidine and phenothiazine moieties, with the aim to improve the anti-tubercular activity and to reduce the cytotoxic effects. Among the resulting compounds, the indole derivative 12e showed an antimycobacterial activity significantly better than thioridazine and a cytotoxicity 15-fold lower.

THIORIDAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to novel thioridazine analogue compounds of formula (I): wherein R1 is OCH3 or NH2 , particularly suitable to be used in the treatment of pediatric acute myeloid leukemia harboring the t(6;11)(q27;q23) KMT2A/AFDN rearrangement.

The phenothiazine compound and its preparation method and application

The invention relates to a phenothiazine compound and a preparation method thereof. The invention further relates the application of the phenothiazine compound in anti-cancer drug preparation and anti-cancer drugs using the compound as the effective component. The phenothiazine compound has the advantages that the compound with broad-spectrum anti-cancer effect is obtained by modifying phenothiazine ternary interlink parent nucleuses, synthesizing method is simple, and high yield is achieved; the phenothiazine compound has certain restraining effect on human breast cancer cells line MCF-7 and human hepatoma cell line Hep-G2, and a new thought is provided to new drugs satisfying clinic requirements.

THE (S)-ENANTIOMER OF MEPAZINE

The present invention relates to the (S)-enantiomer of mepazine, its applicability in therapy, a pharmacological composition comprising (S)-mepazine, and processes for the preparation of (S)- mepazine and one of its intermediates.

Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase

Second site: In the crystal structure of human MALT1casp-Ig3 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) in complex with the tricyclic phenothiazine derivative thioridazine (violet in the picture), the inhibitor is bound in a hydrophobic pocket far from the active site. This explains the action of phenothiazine derivatives as noncompetitive, reversible inhibitors. Copyright